公开(公告)号：US20210038757A1

公开(公告)日：2021-02-11

申请号：US16945990

申请日：2020-08-03

申请人： Omrix Biopharmaceuticals Ltd. ,  Ethicon, Inc.

发明人： EREZ ILAN ,  OMRI FAINGOLD ,  TAMAR AUERBACH-NEVO ,  TALI NEGREANU-GILBOA ,  HADAS ALPERIN ,  Yi-Lan Allen Wang ,  Dwayne Looney

IPC分类号： A61L15/28 ,  A61L15/42 ,  A61L15/64 ,  A61L15/44

摘要： An expandable biodegradable hemostatic matrix comprised of oxidized cellulose, and having a density ranging from about 0.8 to about 1.2 gr/cm3 is disclosed herein. The matrix may be expandable to at least 3 times its original volume within 4 sec upon contact with an aqueous solution room temperature. Further disclosed are methods for making the hemostatic matrix as well as method of treating a wound.

公开(公告)号：US20190184052A1

公开(公告)日：2019-06-20

申请号：US16195898

申请日：2018-11-20

申请人： Omrix Biopharmaceuticals Ltd.

发明人： EREZ ILAN ,  OMRI FAINGOLD

IPC分类号： A61L15/32 ,  A61F13/02 ,  A61L15/42

CPC分类号： A61L15/32 ,  A61F13/00063 ,  A61F13/0203 ,  A61F13/0253 ,  A61F13/0289 ,  A61F2013/00931 ,  A61L15/425 ,  A61L31/046

摘要： The invention provides a wound dressing made by an ex vivo formed combination of fibrinogen and/or fibrin containing-liquid formulation and an oxidized cellulose (OC) backing; and use thereof.

公开(公告)号：US20230190993A1

公开(公告)日：2023-06-22

申请号：US18080815

申请日：2022-12-14

申请人： Omrix Biopharmaceuticals Ltd. ,  Ethicon, Inc.

发明人： NINA RAVER SHAPIRA ,  ASHLEY DEANGLIS ,  OMRI FAINGOLD

IPC分类号： A61L24/04 ,  A61L15/22 ,  A61L15/42

CPC分类号： A61L24/043 ,  A61L15/225 ,  A61L15/425 ,  A61L2400/04

摘要： The invention relates to compositions comprised of albumin and clottable proteins including fibrinogen and to use thereof e.g., for treating bleeding. In particular, the compositions are comprised of albumin and one or more clottable proteins, wherein the albumin and the one or more clottable proteins are present at a total concentration of at least 90% by total protein weight, wherein the clottable protein fibronectin is present at an amount of less than about 0.5% by total protein weight or is absent, and wherein the weight ratio of the albumin to the clottable protein fibrinogen is at least 1:15, respectively.

公开(公告)号：US20220354986A1

公开(公告)日：2022-11-10

申请号：US17869978

申请日：2022-07-21

申请人： Omrix Biopharmaceuticals Ltd.

发明人： EREZ ILAN ,  OMRI FAINGOLD

IPC分类号： A61L15/32 ,  A61F13/02 ,  A61F13/00 ,  A61L15/42 ,  A61F17/00

摘要： The invention provides a wound dressing made by an ex vivo formed combination of fibrinogen and/or fibrin containing-liquid formulation and an oxidized cellulose (OC) backing; and use thereof.